表紙
市場調查報告書

第一型糖尿病 (幼年型糖尿病) :開發中產品分析

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232787
出版日期 內容資訊 英文 684 Pages
訂單完成後即時交付
價格
Back to Top
第一型糖尿病 (幼年型糖尿病) :開發中產品分析 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 684 Pages
簡介

所謂第一型糖尿病 (幼年型糖尿病) ,是胰臟中斷生產胰島素的自體免疫疾病。由於人體的免疫系統攻擊、破壞胰臟內部的胰島素生產細胞 (β細胞)而發病。主要的易罹病素質有先天性疾病和家族病史、胰臟疾病、感染疾病等。主要的前兆、症狀有嚴重的乾渴和頻繁的尿意、極度的空腹感、體重減少、倦怠感、易怒,非日常性行動等。在治療時,必須改善生活習慣和定時藥物治療。

本報告提供全球第一型糖尿病 (幼年型糖尿病) 治療藥的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢和臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

型糖尿病 (幼年型糖尿病)的概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11765IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 3, 11, 35, 23, 1, 115, 23 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 2, 1, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Type 1 Diabetes (Juvenile Diabetes) - Overview
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
  • Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..12), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H2 2019
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H2 2019
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H2 2019

List of Figures

  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top